4.7 Article

Metallothionein III (MT3) is a putative tumor suppressor gene that is frequently inactivated in pediatric acute myeloid leukemia by promoter hypermethylation

期刊

JOURNAL OF TRANSLATIONAL MEDICINE
卷 12, 期 -, 页码 -

出版社

BMC
DOI: 10.1186/1479-5876-12-182

关键词

Metallothionein III; Pediatric acute myeloid leukemia; Methylation; Tumor suppressor

资金

  1. National Key Basic Research Program [2010CB933902]
  2. Key Medical Subjects of Jiangsu Province [XK201120]
  3. Innovative Team of Jiangsu Province [LJ201114, LJ201126]
  4. Special Clinical Medical Science and Technology of Jiangsu Province [BL2012050, BL2013014]
  5. Key Laboratory of Suzhou [SZS201108, SZS201307]
  6. National Natural Science Foundation [81100371, 81370627, 81300423, 81272143]
  7. Natural Science Foundation of Jiangsu Province [BK2011308]
  8. Universities Natural Science Foundation of Jiangsu Province [11KJB320014]
  9. Talent's Subsidy Project in Science and Education of Department of Public Health of Suzhou City [SWKQ1020]
  10. Major Scientific and Technological Special Project for Significant New Drugs Creation [2012ZX09103301-040]

向作者/读者索取更多资源

Background: Acute myeloid leukemia (AML) is the second most common form of leukemia in children. Aberrant DNA methylation patterns are a characteristic feature in various tumors, including AML. Metallothionein III (MT3) is a tumor suppresser reported to show promoter hypermethylated in various cancers. However, the expression and molecular function of MT3 in pediatric AML is unclear. Methods: Eleven human leukemia cell lines and 41 pediatric AML samples and 20 NBM/ITP (Norma bone marrow/Idiopathic thrombocytopenic purpura) control samples were analyzed. Transcription levels of MT3 were evaluated by semi-quantitative and real-time PCR. MT3 methylation status was determined by methylation specific PCR (MSP) and bisulfite genomic sequencing (BSG). The molecular mechanism of MT3 was investigated by apoptosis assays and PCR array analysis. Results: The MT3 promoter was hypermethylated in leukemia cell lines. More CpG's methylated of MT3 was observed 39.0% pediatric AML samples compared to 10.0% NBM controls. Transcription of MT3 was also significantly decreased in AML samples compared to NBM/ITP controls (P < 0.001); patients with methylated MT3 exhibited lower levels of MT3 expression compared to those with unmethylated MT3 (P = 0.049). After transfection with MT3 lentivirus, proliferation was significantly inhibited in AML cells in a dose-dependent manner (P < 0.05). Annexin V assay showed that apoptosis was significantly upregulated MT3-overexpressing AML cells compared to controls. Real-time PCR array analysis revealed 34 dysregulated genes that may be implicated in MT3 overexpression and apoptosis in AML, including FOXO1. Conclusion: MT3 may be a putative tumor suppressor gene in pediatric AML. Epigenetic inactivation of MT3 via promoter hypermethylation was observed in both AML cell lines and pediatric AML samples. Overexpression of MT3 may inhibit proliferation and induce apoptosis in AML cells. FOXO1 was dysregulated in MT3-overexpressing cells, offering an insight into the mechanism of MT3 induced apoptosis. However, further research is required to determine the underlying molecular details.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据